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Inhaled corticosteroids (ICSs) improve asthma disease control; once-daily ICS administration
may have advantages for patients. Our objective was to assess the efficacy and safety of
the novel ICS fluticasone furoate (FF) over 24 weeks versus placebo.
This was a 24-week double-blind, double-dummy, placebo- and active-controlled study
(NCT01159912) of 343 asthma patients (12 years) not controlled by their current ICS. Patients
were randomised (1:1:1) to FF100 mg, placebo (both administered once-daily [OD] via3427282; fax: þ46 31 415239.
(J. Lo¨tvall).
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42 J. Lo¨tvall et al.ELLIPTA dry powder inhaler in the evening) or fluticasone propionate (FP) 250 mg (adminis-
tered twice-daily (BD) via DISKUS/ACCUHALER). Primary endpoint was change from base-
line in pre-dose evening forced expiratory volume in 1s (FEV1) at Week 24; change from
baseline in % rescue-free 24-h periods was a powered secondary endpoint. Adverse events
(AEs) were assessed.
FF100 mg OD and FP250 mg BD significantly improved pre-dose evening FEV1 compared with
placebo at Week 24 (þ146 ml [pZ 0.009] and þ145 ml [pZ 0.011], respectively). Percentage
of rescue-free 24-h periods was increased with FF100 mg OD (þ14.8%) and FP250 mg BD
(þ17.9%) compared to placebo (both p < 0.001). On-treatment AEs were reported by 53%
(FF100 mg OD), 42% (FP250 mg BD) and 40% (placebo) of patients. On-treatment severe asthma
exacerbations were lower with FF100 mg OD (3%) and FP250 mg BD (2%) than placebo (7%).
There was significant suppression of urinary cortisol at week 24 with FF100 mg OD
(p Z 0.030) and FP250 mg BD (p Z 0.036) relative to placebo.
FF100 mg OD, administered in the evening, achieves significant improvements in lung func-
tion and rescue inhaler use over 24 weeks, comparable to FP250 mg BD with similar safety pro-
file.
ª 2013 The Authors. Published by Elsevier Ltd.Open access under CC BY-NC-ND license.Introduction
Inhaled corticosteroids (ICS) are the cornerstone of therapy
for all severities of persistent asthma, with benefits
including control of asthma symptoms, improvements in
lung function and a decrease in airway hyper-
responsiveness [1]. However, there continues to be poten-
tial to improve disease control in adults and children,
especially from the perspective of adherence which, when
low, can contribute to poor asthma control [1e3].
Fluticasone furoate (FF) is a novel ICS in development
for once-daily (OD) use in asthma. Structurally, FF is
distinct from the twice-daily (BD) ICS, fluticasone propio-
nate (FP) [4]. Preclinically, FF exhibits a greater anti-
inflammatory activity than FP [5,6]. Clinically, FF, admin-
istered once-daily in the evening is non-inferior to the same
daily dose administered twice daily with respect to lung
function [7]; exhibits significant effects versus placebo with
respect to lung function over a range of doses and asthma
severities [8e10]; has shown a significant effect on the
allergen-induced early asthmatic response 23e24 h after
dosing [11]; and is indicated as a once-daily therapy for
allergic rhinitis [12,13].
Dose-ranging studies of FF performed over 8 weeks have
shown that the 100 mg dose provides a significant benefit in
asthma [8,9], and exhibits similar lung function effects to
FP250 mg BD in patients uncontrolled by low-dose ICS alone
[9]. The present study sought to determine further whether
this dose of FF (hereafter referred to as FF100 mg OD), given
once-daily in the evening, is effective and tolerable over a
longer period in patients with asthma uncontrolled by their
current ICS. The primary endpoint was the effect of
FF100 mg OD on lung function measured approximately 24-h
post-dose at Week 24; secondary endpoints included
symptomatic assessments of asthma, and safety was also
assessed. The study was placebo-controlled and included
FP250 mg BD as a reference arm for internal validation of
results; it was not designed to assess non-inferiority or
equivalence of FF100 mg OD to FP250 mg BD. Some of the
results from this study have been presented in abstract
form [14].Methods
Patients
Patients were required to be 12 years of age with a
diagnosis of asthma [15] for 12 weeks and maintained on a
stable dose of ICS for 4 weeks prior to the screening visit.
A pre-bronchodilator forced expiratory volume in 1s (FEV1)
of 40e90% predicted, adjusted for ethnicity [16], and
evening reversibility of 12% and 200 ml following albu-
terol/salbutamol inhalation were also required. Patients
were required to be current non-smokers (3 months) with
a smoking history of less than 10 pack-years. Long-acting
beta2 agonists were not permitted within 4 weeks of the
screening visit. The study was approved by local ethics
review committees and was conducted in accordance with
the Declaration of Helsinki and Good Clinical Practice
guidelines. Written informed consent from each adult (18
years) patient was obtained prior to performing any study-
specific procedures, as was assent and written parental
consent for each adolescent (12e17 years) patient.Study design
This was a 24-week, randomised, multicentre, placebo- and
active-controlled, double-blind, double-dummy, parallel-
group study (GSK study FFA112059; ClinicalTrials.gov
NCT01159912) conducted at 56 centres in five countries
between 30 June 2010 and 16 January 2012. Eligible pa-
tients entered a 4-week run-in period during which they
were maintained on their stable dose of ICS (long-acting
beta2 agonists were not permitted), switched their rescue
short-acting beta2 agonist (SABA) to albuterol/salbutamol,
and recorded symptoms, rescue use and morning/evening
peak expiratory flow (PEF) in an electronic daily diary.
Patients were eligible for randomisation if at the end of the
4-week run-in period they were (i) uncontrolled on their
stable dose of run-in ICS medication, i.e. exhibited an
evening pre-dose FEV1 40e90% of predicted and reported
an asthma symptoms score of 1 and/or rescue use on 4 of
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baseline medication and daily diary completion on 4 of the
last 7 days of the run-in period.
The central randomisation schedule was generated by
the sponsor using a validated computerised system (Ran-
dAll). Subjects were randomised using the Registration and
Medication Ordering System (RAMOS), which was used by
the study investigators or their designees to register and
randomise the patients and receive their medication
assignment information. Patients were randomised 1:1:1 to
receive placebo, FF100 mg OD or FP250 mg BD. FF100 mg OD
was administered in the evening (5 pme11 pm) via the
ELLIPTA dry powder inhaler (DPI) (representing an
emitted dose of 92 mg) (ELLIPTA is a trademark of the
GlaxoSmithKline group of companies). Evening dosing for FF
was employed based on prior studies which indicated once-
daily evening dosing is as efficacious as the same daily dose
given twice daily, compared to once-daily morning dosing
where a numerical advantage was observed with the same
daily dose given twice daily [17]. FP250 mg BD was admin-
istered in the morning and evening via the DISKUS/
ACCUHALER device. Placebo was administered once-daily
in the evening via the ELLIPTA DPI or twice daily via the
DISKUS/ACCUHALER as appropriate. To maintain the study
blind each patient received an ELLIPTA DPI (from which
they inhaled once-daily in the evening) and a DISKUS/
ACCUHALER (from which they inhaled twice daily). Study
visits took place at Weeks 2, 4, 8, 12, 16, 20 and 24; follow-
up contact was conducted up to 1 week after completing
study medication.
Assessments
The primary endpoint was mean change from baseline in
pre-dose evening FEV1 at 24 weeks. FEV1 was measured
electronically by spirometry at 5e11 pm using standard
techniques. The mean change from baseline in the per-
centage of rescue-free 24-h periods over the 24 weeks of
the study was a powered secondary endpoint. Additional
secondary endpoints comprised mean change over the
study period from baseline in evening/morning PEF and
percentage of symptom-free 24-h periods. Change from
baseline in the Asthma Quality of Life Questionnaire for 12
years and older (AQLQþ12; Qoltech, Bosham, UK) score at
weeks 12 and 24 was also a secondary endpoint. Other
endpoints were the change from baseline in the Asthma
Control Test (ACT: QualityMetric, Inc. Lincoln, RI, USA)
score at weeks 12 and 24, and withdrawal due to lack of
efficacy. The AQLQþ12 and ACT were administered at
baseline and Study Visits 6 and 9 (Weeks 12 and 24).
Safety endpoints comprised the incidence of adverse
events (AEs) and serious AEs (SAEs). Asthma exacerbations,
defined as the need for oral or systemic corticosteroids for
3 days, or any hospitalisation requiring oral or systemic
corticosteroids, and worsening of asthma, defined as the
need for treatment additional to study medication and
rescue medication were also assessed (but not specified as
safety endpoints); as was pneumonia (confirmed by chest X-
ray) and oral/oropharyngeal candidiasis (assessed by
oropharyngeal examination at each study visit and recorded
as an AE if present). Standard laboratory parameters
(haematology, clinical chemistry) and vital signs wereassessed at baseline, 24 h-urine cortisol (UC) excretion was
assessed at baseline and study end.
Statistical analysis
The primary comparison of interest was the difference be-
tween FF100 mg OD and placebo, while FP250 mg BD was also
compared to placebo. The primary endpoint was pre-dose
evening FEV1 at Week 24 using last observation carried for-
ward. This was assessed by analysis of covariance. The ma-
jority of the powered secondary, secondary and other
endpoint comparisons were analysed using the same
approach. AQLQþ12 and ACTwere analysed using a repeated
measuresmodel andwithdrawals due to lack of efficacywere
analysed using Fisher’s Exact test. To account formultiplicity
across key endpoints a step-down closed testing procedure
was employed (see additional methods in Online
Supplementary Material). No formal analysis of differences
between FF100 mg OD and FP250 mg BD was planned prior to
the study; however the relative effects of FF100 mg OD and
FP250 mg BD could be assessed by comparison of point esti-
mates for FF100 mg OD versus placebo comparisons, and
whether they laywithin the 95% confidence interval for point
estimates of FP250 mg BD versus placebo comparisons.
Additional detailed methods are provided in the Online
Supplementary Material.
Results
Study population
Of 1036 patients screened, 349 were randomised, resulting
in an intention-to-treat (ITT) population of 343, of whom
255 completed the study (Fig. 1). The most common reason
for early withdrawal was lack of efficacy which included
asthma exacerbations, most of which occurred in the pla-
cebo group. Demographic and patient baseline character-
istics are shown in Table 1. The majority of study patients
were white (79%) or of African heritage/AfricaneAmerican
(19%), the mean (standard deviation [SD]) duration of
asthma was 18.28 (14.006) years. ICSs most frequently used
during prior to screening and during run-in were FP
(42e48%) or budesonide (26e29%).
Efficacy
Primary endpoint
Pre-dose evening FEV1 was significantly improved at Week 24
relative toplacebobybothFF100mgODandFP250mgBD;both
active treatments resulted in similar effects compared with
placebo (Table 2). Results for the PP population replicated
those for the ITT population (Online Supplementary Material,
Table 1). Over the study a small increase in pre-dose evening
FEV1 was observed in the placebo-treated group but both
FF100 mg OD and FP250 mg BD caused greater effects (Fig. 2/
Online Supplementary Material, Fig. 1).
Powered and other secondary endpoints
The percentage of rescue-free 24-h periods was signifi-
cantly increased compared with placebo for both FF100 mg
Figure 1 Patient disposition. BD, twice daily; FF, fluticasone furoate; FP, fluticasone propionate; ITT, intention-to-treat; OD,
once-daily.
44 J. Lo¨tvall et al.OD and FP250 mg BD (Table 2). In a post-hoc sensitivity
analysis no difference from placebo was observed for
change from baseline in evening PEF with FF100 mg OD
(Table 2). The rationale for the post-hoc sensitivity analysis
and time-course figures for evening and morning PEF are
provided in the Online Supplementary Material (Additional
Methods and Fig. 2). Initial analysis of evening PEF found
no significant difference between placebo and active
therapy (Online Supplementary Material Table 2) meaning
significance (regardless of p-value) could not be inferred for
all subsequent efficacy comparisons because of the step-
down closed testing procedure employed. Morning PEF,
percentage of symptom-free 24-h periods over the courseTable 1 Baseline characteristics (intention-to-treat population
Placebo N Z 11
Age (years), mean (SD) 40.3 (17.68)
Female sex, n (%) 68 (59)
Pre-bronchodilator FEV1 (l) mean (SD) 2.326 (0.6493)
Predicted baseline FEV1 (%) mean (SD) 72.32 (10.871)
Reversibility (%) mean (SD) 25.43 (12.959)
Symptom-free 24-h periods (%) mean (SD) 3.9 (10.58)
Rescue-free 24-h periods (%) mean (SD) 18.5 (29.19)
AQLQþ12, mean (SD) 4.95 (0.971)
Asthma Control Test, mean (SD) 15.9 (3.23)
Asthma Control Test<20, n (%) 100 (87)
AQLQþ12, Asthma Quality of Life Questionnaire for 12 years and o
fluticasone furoate; FP, fluticasone propionate; OD, once-daily; SD, sof the study and AQLQþ12 at Weeks 12 and 24 were
numerically improved by both active treatments compared
with placebo (Table 2). Least squares (LS) mean changes
from baseline in the AQLQþ12 at week 24 were þ0.51,
þ0.84 and þ0.68 units in the placebo, FF100 mg OD and
FP250 mg BD arms, respectively.
Other outcomes
Improvements from baseline ACT score were observed for
both active treatments compared with placebo at weeks 12
and 24 (Table 2). LS mean changes from baseline were þ2.5
in the placebo arm, þ3.9 in the FF100 mg OD arm and þ3.6).
5 FF100 mg OD N Z 114 FP250 mg BD N Z 114
40.1 (16.17) 41.4 (15.64)
63 (55) 72 (63)
2.374 (0.6285) 2.364 (0.7256)
72.18 (10.387) 73.04 (11.936)
27.32 (15.252) 25.07 (14.537)
7.9 (20.45) 7.0 (20.99)
13.3 (24.52) 17.1 (30.49)
4.81 (1.132) 4.76 (1.040)
15.4 (3.77) 15.4 (3.53)
98 (86) 100 (88)
lder; BD, twice daily; FEV1, forced expiratory volume in 1s; FF,
tandard deviation.
Table 2 Treatment differences between active therapy and placebo for primary and secondary endpoints (intention-to-treat
population).
FF100 mg OD vs. placebo FP250 mg BD vs. placebo
Pre-dose evening FEV1 (l): difference in LS mean change
from baseline (95% CI) at week 24 (LOCF)
0.146 (0.036, 0.257)
p Z 0.009
0.145 (0.033, 0.257)
p Z 0.011
Rescue-free 24-h periods (%): difference in LS mean change
from baseline (95% CI) over weeks 1e24
14.8 (6.9, 22.7)
p < 0.001
17.9 (10.0, 25.7)
p < 0.001
Evening PEF (l/min): difference in LS mean change from
baseline (95% CI) over weeks 1e24a
5.8 (1.9, 13.6)
p Z 0.141
8.3 (0.6, 16.1)
p Z 0.036
Morning PEF (l/min): difference in LS mean change from
baseline (95% CI) over weeks 1e24a
11.0 (3.4, 18.7)
e
6.6 (1.1, 14.2)
e
Symptom-free 24-h periods (%): difference in LS mean
change from baseline (95% CI) over weeks 1e24
8.9 (1.1, 16.7)
e
8.8 (1.1, 16.6)
e
AQLQþ12 (units): difference in LS mean change from
baseline (95% CI) at week 12
0.24 (0.03, 0.45)
e
0.28 (0.07, 0.49)
e
AQLQþ12 (units): difference in LS mean change from
baseline (95% CI) at week 24
0.33 (0.09, 0.57)
e
0.16 (0.08, 0.41)
e
Asthma Control Test (units): difference in LS mean
change from baseline (95% CI) at week 12
1.8 (0.8, 2.7)
e
1.6 (0.6, 2.5)
e
Asthma Control Test (units): difference in LS mean
change from baseline (95% CI) at week 24
1.4 (0.4, 2.5)
e
1.1 (0.1, 2.1)
e
AQLQþ12, Asthma Quality of Life Questionnaire for 12 years and older; BD, twice daily; CI, confidence interval; FEV1, forced expiratory
volume in 1s; FF, fluticasone furoate; FP, fluticasone propionate; LOCF, last observation carried forward; LS, least squares; OD, once-
daily; PEF, peak expiratory flow; SD, standard deviation.
a Post-hoc sensitivity analysis; initial analysis results and rationale for sensitivity analysis presented online; p-values are not indicated
for endpoint comparisons below evening PEF in the testing hierarchy due to the closed step-down approach employed.
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patients exhibited an ACT score of 20, indicating well-
controlled asthma, in the placebo, FF100 mg OD and
FP250 mg BD groups respectively. At Week 24 the corre-
sponding percentages of patients with ACT score 20 were
48%, 55% and 51%, respectively. Twenty percent of patients
withdrew due to lack of efficacy with placebo treatment.
For FF100 mg OD and FP250 mg BD 13% and 12% of patients
withdrew for the same reason, respectively. As illustrated
in Online Supplementary Material Fig. 3, both activeFigure 2 Repeated measures analysis of change from base-
line in pre-dose evening FEV1 over 24 weeks (intention-to-treat
population). BD, twice daily; CI, confidence interval; FEV1,
forced expiratory volume in 1s; FF, fluticasone furoate; FP,
fluticasone propionate; LS, least squares; OD, once-daily.treatments resulted in lower withdrawal rates compared
with placebo.
Safety
A greater number of AEs, drug-related AEs and on-
treatment AEs was observed with FF100 mg OD therapy
compared with FP250 mg BD or placebo; no difference was
apparent in the number of patients experiencing AEs
leading to withdrawal (Table 3). Drug-related AEs in 2
patients are listed in (Online Supplementary Material Table
3). On-treatment candidiasis (oral or oropharyngeal)
occurred more frequently with FF100 mg OD (n Z 6) than
with FP250 mg BD (nZ 2) or placebo (nZ 0). A total of nine
on-treatment or post-treatment SAEs were reported in
seven patients. Pyelonephritis and meningitis were re-
ported by one patient each with placebo treatment. Ab-
scess, Crohn’s disease and epididymal cyst were reported
by one patient each with FF100 mg OD treatment; one
further patient receiving FF100 mg OD reported prostate
cancer, Escherichia bacteraemia and pyelonephritis. Sup-
raventricular tachycardia was reported by one patient
receiving FP250 mg BD. The occurrence of Crohn’s disease
was the only SAE that led to withdrawal; none of the SAEs
were considered to be related to the study drug. No deaths
(asthma-related or otherwise) occurred during the study,
nor did any asthma-related hospitalisations.
Severe on-treatment asthma exacerbations occurred in
three (3%) patients receiving FF100 mg OD, two (2%)
receiving FP250 mg BD and eight (7%) receiving placebo. All
of these events were managed with systemic/oral cortico-
steroids. The least squares (LS) mean ratio to baseline at
Table 3 Summary of AEs (intention-to-treat population).
n (%) Placebo
N Z 115
FF100 mg OD
N Z 114
FP250 mg
BD N Z 114
On-treatment AEs 46 (40) 60 (53) 48 (42)
Drug-related AEsa,b 7 (6) 11 (10) 7 (6)
AEs leading to
withdrawalb
2 (2) 3 (3) 3 (3)
On-treatment SAEs 2 (2) 4 (4) 1 (<1)
Drug-related SAEs 0 0 0
SAEs leading to
withdrawal
0 1 (<1) 0
On-treatment AEs
occurring in 5%
of patients
Bronchitis 7 (6) 8 (7) 4 (4)
Headache 5 (4) 7 (6) 7 (6)
Nasopharyngitis 6 (5) 9 (8) 4 (4)
Upper respiratory
tract infection
6 (5) 7 (6) 6 (5)
AE, adverse event; BD, twice daily; FF, fluticasone furoate; FP,
fluticasone propionate; OD, once-daily; SAE, serious adverse
event.
a As deemed by the investigator.
b On-treatment and post-treatment.
46 J. Lo¨tvall et al.week 24 for LS geometric mean 24-h UC was 1.15 for pla-
cebo, 0.88 for FF100 mg OD and 0.88 for FP250 mg BD (UC
population; Supplementary Online Material Fig. 4). Analysis
of these ratios indicated significant differences between
placebo and FF100 mg OD (0.76 [95% confidence interval
{CI}: 0.60, 0.97] p Z 0.030) and between placebo and
FP250 mg BD (0.77 [95% CI 0.60, 0.98] p Z 0.036). No dif-
ference was apparent between FF100 mg OD and FP250 BD.
Discussion
The principal findings of this study were that (i) FF100 mg
OD dosed in the evening over 24 weeks significantly
improved lung function (pre-dose evening FEV1) relative to
placebo; (ii) the effect observed on lung function seen with
FF100 mg OD was similar to that observed with FP250 mg BD;
(iii) improvements in pre-dose evening FEV1 with FF100 mg
OD and FP250 mg BD were observed at the first time point
assessed (Week 2), and were maintained throughout the
study period; (iv) the percentage of 24-h periods free from
the use of rescue medication was significantly improved
with both FF100 mg OD and FP250 mg BD compared with
placebo; and (v) a higher incidence of AEs was observed
with FF100 mg OD compared to FP250 mg BD or placebo,
though no difference was seen in the number of patients
with AEs leading to withdrawal, and no SAEs were consid-
ered related to study medication.
Clinical decision-making in asthma is guided by the
concept of asthma control [1] which is based on the fre-
quency of symptoms and rescue use, the limitation of ac-
tivities and pre-bronchodilator lung function; this approach
has been prospectively assessed, with the majority of, but
not all, patients studied achieving asthma control with an
ICS or ICS/long-acting beta2 agonist combination [18]. Inthe present study FF100 mg OD resulted in significant ef-
fects on both pre-dose evening FEV1 and the percentage of
rescue 24-h periods, compared with placebo; both of these
endpoints are elemental components of the assessment of
asthma control. That the effects seen on these endpoints
with FF100 mg OD were similar to those achieved with
FP250 mg BD suggests similar efficacy between the two
therapies. Our study cohort was well matched across
treatment groups and indicated that patients were using
rescue medication most days at baseline and exhibited an
FEV1 that was approximately 72e73% of predicted, despite
the use of a stable dose of ICS prior to study entry; i.e. at
baseline the population was uncontrolled. This was also
reflected by the majority of patients exhibiting an ACT
score of 20 at baseline and a mean baseline ACT score of
15.4 in both active treatment arms and 15.9 in the placebo
arm. Despite this level of uncontrolled asthma both
FF100 mg OD and FP250 mg BD exhibited numerically greater
effects than placebo on ACT, percentage of symptom-free
24-h periods and quality of life. However, it should be
noted that while the minimally important difference (MID)
for a change in ACT of 3 units [19] was not achieved versus
placebo for either active therapy, the percentage of pat-
ents achieving well-controlled asthma (i.e. ACT 20) was
greater in the ICS treatment groups than in those on pla-
cebo at the end of the 24-week treatment period, and the
change from baseline did reach the MID with both active
therapies but not with placebo. Equally, while the MID of
0.5 points [20] was not achieved for the AQLQþ12 versus
placebo for either active therapy it was achieved versus
baseline in both active treatment arms. The observation
that the MID for the AQLQþ12 was also achieved in the
placebo arm (þ0.51 units) may have been due to a healthy
survivor effect, as more patients withdrew from the pla-
cebo arm than the FF100 mg OD or FP250 mg BD arms. These
findings suggest that the effects of FF100 mg OD and
FP250 mg BD on lung function, rescue use and symptom-free
24-h periods translated to a trend for improvement in the
perception of symptoms and quality of life, albeit one that
was not clinically important relative to placebo. Although
statistical inference cannot be drawn from these compari-
sons it is apparent that the overall trend for effect suggests
that FF100 mg OD has a positive effect on all of the key
criteria related to the modern management of asthma. The
findings with the active control (FP250 mg BD) suggest the
study population was responding as expected to an estab-
lished ICS; that the magnitude of the differences observed
between FF100 mg OD and placebo, and FP250 mg OD and
placebo were similar suggests the two ICS treatments had
similar therapeutic effects.
The 100 mg dose of FF has previously been shown to
improve pre-dose evening FEV1 relative to placebo in
asthma patients uncontrolled by a SABA alone [8] or un-
controlled on a low-dose ICS [9] over a period of 8 weeks.
This improvement, though numerically lower in our study
compared with the prior studies [8,9] was still statistically
significant and was maintained for the 6-month duration of
the study. The lower magnitude of effect observed in the
present study possibly reflects differences in study design,
patient cohort as determined by inclusion criteria, or other
differences. It is important to note that the difference for
FP250 mg BD versus placebo in our study was also lower than
Fluticasone furoate 100 mg once daily for asthma 47that recorded in previous studies of FP in asthma [21].
Improvements in lung function with ICS treatment vary
greatly in different patients and studies [21], making it
difficult to compare across studies. Furthermore, the
overall level of asthma control in the Western world has
increased over the last 20 years [22]; these observations
may also have contributed to the effects observed here
with FF100 mg OD and FP250 mg BD.
An important difference between the two active treat-
ments, from a patients’ perspective, is once- versus twice-
daily dosing. Studies in a number of diseases, including
cardiovascular disease [23] and hypertension [24], have
shown that adherence to medication is increased with an
OD versus a BD treatment regimen. Similar findings have
been reported in asthma [25,26]. While an association be-
tween adherence and asthma control is known [27] the
question remains as to whether OD dosing results in an in-
crease in adherence in a ‘real-world’ setting, and whether
any increase in adherence translates to an increase in
asthma control.
Similar percentages (w40%) of patients reported AEs
with placebo or FP250 mg BD treatment, while AEs with
FF100 mg OD were reported by an additional w10% of pa-
tients. This increase in the total number of AEs reported
with FF100 mg OD was primarily caused by a greater prev-
alence of rare events reported by one or two patients in the
FF100 mg OD compared with the FP250 mg BD and placebo
groups; i.e. no novel AE signal was observed with FF100 mg
OD. A small but significant reduction in urinary cortisol was
observed after 24 weeks of treatment with both FF100 mg
OD and FP250 mg BD, an observation that has been reported
in a 4-week study of FF100 mg/FF200 mg OD [7] and in a 12-
week study of FF100 mg combined with the OD long-acting
beta2 agonist vilanterol [28]. However, these findings
contrast with those of previous studies of FF100 mg OD
assessed over 8-weeks [8,9,17] or 12-weeks [28], or with
FF100 mg/FF200 mg OD combined with vilanterol over 24
weeks [29,30] or 52 weeks [31]. Serum cortisol is a more
sensitive and reliable measure of cortisol secretion than
urine sampling and in a 6-week study involving complete
24-h serum cortisol profiling (with 0e24 h weighted mean
serum cortisol as the primary endpoint), FF/VI 100/25 mcg
and FF/VI 200/25 mcg OD did not suppress serum cortisol
(treatment ratio [95% CI] to placebo: 0.99 (0.87, 1.12) and
0.97 (0.86, 1.10), respectively) [32]. Corticosteroids,
inhaled or otherwise, have the potential to induce adrenal
suppression particularly when used at high doses, for a long
duration, or by children [33e35]. The balance of evidence
from studies of up to 52 weeks in duration, including the
serum cortisol findings, suggests that clinical doses of FF (or
FF/vilanterol) are unlikely to induce clinically relevant re-
ductions in urinary cortisol, but further longer-term studies
are warranted to assess any potential effect on cortisol
levels in susceptible patients.
The current study included patients with asthma un-
controlled by their current ICS (who were therefore
representative of the patient population in which FF100 mg
OD may be used), was of sufficient duration to determine
longer-term benefits and adverse events, and was both
placebo- and active-controlled. The step-down closed sta-
tistical testing procedure employed represents both a
strength and a limitation. This approach is a rigorous meansof accounting for multiplicity of comparisons. In this study
it meant, consequently, that no significance could be
inferred for comparisons of morning and evening PEF,
symptoms, quality of life and measures of asthma control.
Another limitation of this study is that it was not powered
or designed to analyse non-inferiority of FF100 mg OD and
FP250 mg BD. Furthermore, even though many asthma pa-
tients are smokers [36] these individuals were excluded, to
avoid any overlap with chronic obstructive pulmonary dis-
ease and chronic bronchitis, as is typical of most asthma
clinical trials. This is relevant, as smoking is known to have
a detrimental effect on the response to ICS in asthma pa-
tients [37,38] and the efficacy and safety of FF in asthma
patients who smoke remains to be determined. Finally, the
<1 year study duration, and which only covered part of the
Winter/Spring seasons when respiratory viruses are a major
cause of asthmatic exacerbations, could be a possible
limitation but exacerbation frequency was not a focus of
this study (it was a safety endpoint).
In conclusion, this study shows that FF100 mg OD in
asthma patients not controlled by their current ICS therapy
significantly improves pre-dose evening FEV1 and rescue use
to an extent that is similar to that provided by FP250 mg BD,
and is well tolerated.Conflicts of interest
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